Diogo Ramalho1, Sara Correia2, Rodrigo Realista3, Gustavo Rocha2, Helena Alves2, Lúcia Almeida2, Eva Ferreira4, Sara Monteiro2, Maria João Oliveira2, Maria Céu Almeida5,6. 1. Endocrinology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Rua Conceição Fernandes S/N, 4434-502, Vila Nova de Gaia, Portugal. silva.josediogo@gmail.com. 2. Endocrinology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Rua Conceição Fernandes S/N, 4434-502, Vila Nova de Gaia, Portugal. 3. Obstetrics Department, Centro Hospitalar e Universitário de São João. Alameda Professor Hernâni Monteiro, 4200-319, Porto, Portugal. 4. Nutrition Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Rua Conceição Fernandes S/N, 4434-502, Vila Nova de Gaia, Portugal. 5. Obstetrics Department, Maternidade Bissaya Barreto. Rua Augusta 36, 3000-045, Coimbra, Portugal. 6. Diabetes and Pregnancy Study Group of the Portuguese Society of Diabetology, Rua do Salitre 149, 1250-198, Lisbon, Portugal.
Abstract
AIMS: To access the impact of increasing use of metformin on cesarean section and large for gestational age rates, when compared to insulin. METHODS: A retrospective observational study was developed using data from the Portuguese National Registry, between 2011 and 2019, of 5038 Portuguese women with single pregnancies and gestational diabetes treated with metformin and/or insulin. Three groups were defined according to the therapeutic regimen adopted: g1-insulin in monotherapy (n = 3027[60.1%]); g2-metformin in monotherapy (n = 1366[27.1%]); g3-metformin and insulin (n = 645[12.8%]). Multivariate analysis was adjusted for statistically significant covariates. RESULTS: The cesarean section rate in g1 was similar to g2 (g1:36.9% vs. g2:37%, p = 0.982), although g3 was associated with cesarean delivery (g3:43.6% vs. g1:36.9%, p = 0.005; g3:43.6% vs. g1:37.0%, p = 0.002), with no differences reported in the multivariate analysis adjusted for year of delivery and pregestational body mass index. A delivery of a large for gestational age newborn was less frequently observed in g2 than in g1 (g2:4.1% vs. g1:5.4%, p = 0.044) and in g3 (g2:4.1% vs. g3:9.1%, p < 0.001), and in g1, when compared to g3 (g1:5.4% vs. g3:9.1%, p < 0.001). In the multivariate analysis, g2 showed lower odds of delivering a large for gestational age newborn, compared to g1 (β = -0.511, OR = 0.596, CI95% = 0.428-0.832, p < 0.001). CONCLUSIONS: The use of metformin was not associated with higher cesarean section rates, compared to insulin. Instead, it was suggested a protective role of metformin on large gestational age rates. The concomitant use of dual therapy suggests more complex pregnancies, requiring closer surveillance that mitigate serious perinatal and obstetrical outcomes.
AIMS: To access the impact of increasing use of metformin on cesarean section and large for gestational age rates, when compared to insulin. METHODS: A retrospective observational study was developed using data from the Portuguese National Registry, between 2011 and 2019, of 5038 Portuguese women with single pregnancies and gestational diabetes treated with metformin and/or insulin. Three groups were defined according to the therapeutic regimen adopted: g1-insulin in monotherapy (n = 3027[60.1%]); g2-metformin in monotherapy (n = 1366[27.1%]); g3-metformin and insulin (n = 645[12.8%]). Multivariate analysis was adjusted for statistically significant covariates. RESULTS: The cesarean section rate in g1 was similar to g2 (g1:36.9% vs. g2:37%, p = 0.982), although g3 was associated with cesarean delivery (g3:43.6% vs. g1:36.9%, p = 0.005; g3:43.6% vs. g1:37.0%, p = 0.002), with no differences reported in the multivariate analysis adjusted for year of delivery and pregestational body mass index. A delivery of a large for gestational age newborn was less frequently observed in g2 than in g1 (g2:4.1% vs. g1:5.4%, p = 0.044) and in g3 (g2:4.1% vs. g3:9.1%, p < 0.001), and in g1, when compared to g3 (g1:5.4% vs. g3:9.1%, p < 0.001). In the multivariate analysis, g2 showed lower odds of delivering a large for gestational age newborn, compared to g1 (β = -0.511, OR = 0.596, CI95% = 0.428-0.832, p < 0.001). CONCLUSIONS: The use of metformin was not associated with higher cesarean section rates, compared to insulin. Instead, it was suggested a protective role of metformin on large gestational age rates. The concomitant use of dual therapy suggests more complex pregnancies, requiring closer surveillance that mitigate serious perinatal and obstetrical outcomes.
Authors: Trecia A Wouldes; Malcolm Battin; Suzette Coat; Elaine C Rush; William M Hague; Janet A Rowan Journal: Arch Dis Child Fetal Neonatal Ed Date: 2016-02-24 Impact factor: 5.747
Authors: Janet A Rowan; Elaine C Rush; Victor Obolonkin; Malcolm Battin; Trecia Wouldes; William M Hague Journal: Diabetes Care Date: 2011-10 Impact factor: 19.112